Patients with recurrent breast cancer: Does the primary axillary lymph node status predict more aggressive tumor progression?

Breast Cancer Research and Treatment

Volumn 82, Issue 2, 2003, Pages 83-92

  Rack, Brigitte ^a   Janni, Wolfgang ^a   Gerber, Bernd ^a   Strobl, Barbara ^a   Schindlbeck, Christian ^a   Klanner, Elisabeth ^a   Rammel, Gerhard ^a   Sommer, Harald ^a   Dimpfl, Thomas ^b   Friese, Klaus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KLINIKUM KASSEL   (Germany)

Author keywords

Breast neoplasm; Lymph node status; Neoplasm recurrence; Survival after relapse; Tumor biology

Indexed keywords

ACCOUNTING; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GERMANY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; STANDARD; TUMOR GROWTH; TUMOR VOLUME; UNIVERSITY HOSPITAL;

AXILLA; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; LYMPH NODES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 10744227815     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000003955.73738.9e     Document Type: Article

References (68)

1. Halsted WS: A clinical and histological study of certain adenocarcinoma of the breast and a brief consideration of the supraclavicular operation and of the results of operation for cancer of the breast from 1889 to 1898 at the Johns Hopkins Hospital. Ann Surg 28: 557-576, 1898
2. Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, Mouridsen HT: Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr 19-25, 1992
3. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R, Pilch Y, Glass A, Shibata H, Lerner H, Terz J, Sidorovich L: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. Obstet Gynecol Surv 44: 8-619, 1989
4. Jacobson JA, Danforth DN, Cowan KH, D'Angelo T, Steinberg SM, Pierce L, Lippman ME, Lichter AS, Glatstein E, Okunieff P: Ten-year results of a comparison of conservation with mastectomy in the treatment of stages I and II breast cancer. New Engl J Med 332: 14-911, 1995
5. Sarrazin D, Le MG, Arriagada R, Contesso G, Fontaine F, Spielmann M, Rochard F, Le Chevalier T, Lacour J: Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 14: 3-184, 1989
6. Van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, Van Der SE, Helle PA, Van Zijl K, Bartelink H: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst 92: 14-1150, 2000
7. Veronesi U, Salvadori B, Luini A, Greco M, Saccozzi R, Del Vecchio M, Mariani L, Zurrida S, Rilke F: Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1973 patients. Eur J Cancer 31: 10-1579, 1995
8. Bottcher HD: Radiation therapy of breast cancer Zentralbl Gynakol 113: 21-1161, 1991
9. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942, 1998
10. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjanen K: Mitotic indexes as prognostic predictors in female breast cancer. J Cancer Res Clin Oncol 118: 75-81, 1992
11. Nemoto T, Natarajan N, Bedwani R, Vana J, Murphy GP: Breast cancer in the medial half. Results of 1978 National Survey of the American College of Surgeons. Cancer 51: 1333-1338, 1983
12. Swenson KK, Decher L, Haselow R, Farrell JB, Sperduto PW: Prognostic factors after conservative surgery and radiation therapy for early stage breast cancer. Am J Clin Oncol 21: 111-116, 1998
13. Wilking N, Rutqvist LE, Carstensen J, Mattsson A, Skoog L: Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Acta Oncol 31: 29-35, 1992
14. Guadagnoli E, Shapiro CL, Weeks JC, Gurwitz JH, Borbas C, Soumerai SB: The quality of care for treatment of early stage breast carcinoma: is it consistent with national guidelines? Cancer 83: 302-309, 1998
15. Moore MP, Kinne DW: The surgical management of primary invasive breast cancer. CA Cancer J Clin 45: 279-288, 1995
16. NIH Consensus Conference: Treatment of early-stage breast cancer. JAMA 265: 391-395, 1991
17. Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD: Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87: 1441-1445, 1995
18. Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC: Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 183: 23-27, 2002
19. Orr RK, Hoehn JL, Col NF: The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg 134: 764-767, 1999
20. Pandelidis SM, Peters KL, Walusimbi MS, Casady RL, Laux SV, Cavanaugh SH, Bauer TL: The role of axillary dissection in mammographically detected carcinoma. J Am Coll Surg 184: 341-345, 1997
21. Reynolds C, Mick R, Donohue JH, Grant CS, Farley DR, Callans LS, Orel SG, Keeney GL, Lawton TJ, Czerniecki BJ: Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 17: 1720-1726, 1999
22. Swenson KK, Nissen MJ, Ceronsky C, Swenson L, Lee MW, Tuttle TM: Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol 9: 745-753, 2002
23. Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M: Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 88: 1099-1107, 2000
24. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347: 1233-1241, 2002
25. Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, Falkson G, Falkson HC, Taylor SG, Tormey DC: Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17: 1689-1700, 1999
26. Chua B, Ung O, Boyages J: Treatment of the axilla in early breast cancer: past, present and future. Anz J Surg 71: 729-736, 2001
27. Forrest AP, Everington D, McDonald CC, Steele RJ, Chetty U, Stewart HJ: The Edinburgh randomized trial of axillary sampling or clearance after mastectomy. Br J Surg 82: 1504-1508, 1995
28. Dent DM, Gudgeon CA, Murray EM: Mastectomy with axillary clearance versus mastectomy without it. Late results of a trial in which patients had no adjuvant chemo-, radio- or endocrine therapy. S Afr Med J 86: 670-671, 1996
29. Sinha PS, Thrush S, Bendall S, Bates T: Does radical surgery to the axilla give a survival advantage in more severe breast cancer? Eur J Cancer 38: 1474-1477, 2002
30. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80: 1803-1804, 1997
31. Le DV, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom- Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64: 1914-1921, 1989
32. Bloom HJG, Richardson WW: Histologic grading and prognosis in breast cancer. Br J Cancer 15: 359-377, 1957
33. Genz Th, Schaller G: Das Rezidiv beim Mammakarzinom. Krebsmedizin 11: 15-18, 1990
34. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1958
35. Cox DR: Regression models and life tables. J R Statist Soc B 34: 187-220, 1972
36. Brand TC, Sawyer MM, King TA, Bolton JS, Fuhrman GM: Understanding patterns of failure in breast cancer treatment argues for a more thorough investigation of axillary lymph nodes in node negative patients. Am J Surg 180: 424-427, 2000
37. Kamby C, Rose C, Ejlertsen B, Andersen J, Birkler NE, Rytter L, Andersen KW, Zedeler K: Stage and pattern of metastases in patients with breast cancer. Eur J Cancer Clin Oncol 23: 1925-1934, 1987
38. Mittra I, MacRae KD: A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology? Eur J Cancer 27: 1574-1583, 1991
39. Tubiana-Hulin M, Hacene K, Martin PM, Spyratos F: Prognostic factor clustering in breast cancer: biology or chronology? Eur J Cancer 31A: 282-283, 1995
40. Mueller CB: Stage II breast cancer is not simply a late stage I. Surgery 104: 631-638, 1988
41. Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44: 671-675, 1979
42. Howat JM, Harris M, Swindell R, Barnes DM: The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer 51: 263-270, 1985
43. Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, Swindell R, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1: 588-591, 1984
44. Paterson AH, Zuck VP, Szafran O, Lees AW, Hanson J: Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin Oncol 18: 937-943, 1982
45. Touboul E, Buffat L, Belkacemi Y, Lefranc JP, Uzan S, Lhuillier P, Faivre C, Huart J, Lotz JP, Antoine M, Pene F, Blondon J, Izrael V, Laugier A, Schlienger M, Housset M: Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 43: 25-38, 1999
46. Williams MR, Todd JH, Nicholson RI, Elston CW, Blamey RW, Griffiths K: TI - survival patterns in hormone treated advanced breast cancer. Br J Surg 73: 752-755, 1986
47. Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, Connolly JL, Schnitt SJ, Silver B, Harris JR: Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 11: 1-48, 1993
48. Fowble B, Solin LJ, Schultz DJ, Rubenstein J, Goodman RL: Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int Radiat Oncol Biol Phys 19: 4-842, 1990
49. Clark GM, Sledge Jr GW, Osborne CK, McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5: 55-61, 1987
50. Dunst J, Steil B, Furch S, Fach A, Lautenschlager C, Diestelhorst A, Lampe D, Kolbl H, Richter C: Prognostic significance of local recurrence in breast cancer after postmastectomy radiotherapy. Strahlenther Onkol 177: 504-510, 2001
51. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J: Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56: 67-78, 1999
52. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK: Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 17: 2334-2340, 1999
53. Kamby C, Sengelov L: Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat 45: 181-192, 1997
54. Koenders PG, Beex LV, Kloppenborg PW, Smals AG, Benraad TJ: Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat 21: 173-180, 1992
55. Lionetto R, Pronzato P, Bertelli GF, Ardizzoni A, Conte PF, Rosso R: Survival of patients with relapsing breast cancer: analysis of 302 patients. Oncology 43: 278-282, 1986
56. Shek LLM, Godolphin W: Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 48: 5565-5569, 1988
57. Brunner KW, Harder F, Greiner R, Frost M, Cavalli F, Senn HJ, Schatzmann E: Local relapse after surgery for breast cancer: prognostic factors and therapeutic implications. Schweiz Med Wochenschr 118: 52-1981, 1988
58. Willner J, Kiricuta IC, Kolbl O: Beeinflusse der Primartumor die Prognose bei lokoregionarem Rezidiv nach Mastektomie wegen Mammakarzinom? [Does primary tumor affect the prognosis in postmastectomy locoregional recurrence in breast carcinoma?]. Strahlenther Onkol 171: 18-28, 1995
59. Paradiso A, Ranieri G, Silvestris N, Naccarato G, Bevilacqua G, Mangia A, Leone B, Vallejo C, Simone G, Schittulli F, De Lena M: TI - failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis. 1: 3-132; 2001
60. Leborgne F, Leborgne JH, Ortega B, Doldan R, Zubizarreta E: Breast conservation treatment of early stage breast cancer: patterns of failure. Int J Radiat Oncol Biol Phys 31: 765-775, 1995
61. Pisansky TM, Ingle JN, Schaid DJ, Hass AC, Krook JE, Donohue JH, Witzig TE, Wold LE: Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer 72: 1247-1260, 1993
62. Dhodapkar MV, Ingle JN, Cha SS, Mailliard JA, Wieand HS: Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials. Cancer 77: 683-690, 1996
63. Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C, Hantschmann P, Sommer H, Pantel K, Braun S: The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 92: 46-53, 2001
64. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Tokue Y, Narabayashi M, Adachi I, Takashima S: Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16: 2401-2408, 1998
65. Brunner KW, Harder F, Greiner R, Frost M, Cavalli F, Senn HJ, Schatzmann E: Das loko-regionale Rezidiv nach operiertem Mammakarzinom: prognostische Faktoren und therapeutische Konsequenzen [Loco-regional recurrence following surgery of breast carcinoma: prognostic factors and therapeutic consequences]. Schweiz Med Wochenscht 118: 1976-1981, 1988
66. Haffty BG, Toth M, Flynn S, Fischer D, Carter D: Prognostic value of DNA flow cytometry in the locally recurrent, conservatively treated breast cancer patient. J Clin Oncol 10: 1839-1847, 1992
67. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA: Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse. J Clin Oncol 17: 1449-1457, 1999
68. Kurtz JM, Spitalier JM, Amalric R, Brandone H, Ayme Y, Jacquemier J, Hans D, Bressac C: The prognostic significance of late local recurrence after breast-conserving therapy. Int J Radiat Oncol Biol Phys 18: 1-93, 1990